An Unorthodox Path to Medical Device Success

Innovation is second nature to Joe Landolina. As someone who grew up in an environment that fostered curiosity and learning, with a grandfather who ran a chemistry lab, it’s no surprise that Joe invented the technology of Cresilon’s flagship product Vetigel at the youthful age of 17.

Med Tech Gurus Podcast

This biotech just raised $25M to develop plant-based gel that stops traumatic bleeding in seconds

Bloodtech startups are booming and Cresilon, Inc, a Brooklyn-based biotechnology company is another one in the news. They’re developing and manufacturing a hemostatic medical device to arrest severe bleeding in a matter of seconds without manual pressure, has secured $25M in a Series A-4 financing round led by Paulson Investment Co.

InnovationRx: Healthcare’s 2023 Outlook, Covid Hospitalizations Are Rising And What To Know About RSV

Biotechnology startup Cresilon announced that it raised a $25 million series A-4 round, which will be used in part to accelerate the entry of its product, a plant-based gel that can be applied to wounds to stop bleeding, into the market for human use.

This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresilon and just inked a research partnership with Walter Reed.

Hemostatic Gel Immediately Stops Multiple Types of Bleeds Without Need to Apply Pressure

Cresilon is using recycled algae, meaning algae or kelp that has washed up onto the shoreline. The vendors they work with are highly sustainable as they are not damaging kelp forests but salvaging material that has already washed up on beaches.

Interview: 17-year-old invents life-saving gel technology

When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last year. DDW’s Megan Thomas caught up with Landolina about his success story.

Stopping Bleeding with Algal-Based Polymers

“Catastrophic bleeding is a cause of death after a wide variety of wounds in humans and other animals. This week’s podcast speaks with Joe Landolina from Cresilon, describing natural polymers that immediately cease bleeding, along with their military, medical and veterinary applications.”

How This Plant-Based Gel Can Treat Wounds

“Welcome back to Cheddar Innovates brought to you by Curiosity Stream. Our next guest is bringing innovation to something we’ve all used before: the Band Aid- but he’s bringing it to the next level by creating a gel that instantly stops bleeding and seals wounds from small paper cuts to even major traumatic bleeds. Joining us now is Joe Landolina: CEO and Founder of Cresilon.”

Brooklyn Native Creates Gel Bandage

“There are over three million bleeds every single year in animal health and many more bleeds on the human side that we’re hoping to eventually be able to target,” Landolina said.

Cresilon’s gel used for animals to stop bleeding in seconds

Nov. 08, 2021 – 3:54 – Cresilon CEO Joe Landolina discusses life-saving innovation on Fox Business.

Brooklyn Heights native's company Cresilon creates gel to stop bleeding

Not many college freshmen start a business as soon as they get to school. However, Brooklyn Heights’ Joe Landolina had other plans in mind when starting his company Cresilon Inc. 

Press Releases

Cresilon Announces Distribution Agreement for VETIGEL with Penn Veterinary Supply

NEW YORK (August 22, 2023) — Cresilon Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to veterinarians through Penn Veterinary Supply, an independent U.S. regional distributor of veterinary products and services.

Cresilon Receives First FDA Clearance For Human Use of Hemostatic Gel Technology

June 29, 2023, New York – Cresilon, Inc. (“Cresilon”), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that it has been granted 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for Cresilon Hemostatic Gel™ (“CHG™”).

Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market

This financing will be used to accelerate Cresilon’s global growth plan, increase production capacity at its state-of-the-art biomanufacturing facility in Brooklyn, and expand upon the company’s successful launch of VETIGEL®.

Cresilon and Walter Reed Army Institute of Research Sign Cooperative R&D Agreement for Treatment of Traumatic Brain Injuries

“Cresilon is extremely proud and honored to be supporting the DoD and WRAIR in this critically important work,” said Joe Landolina, CEO of Cresilon. “This collaboration is a testament to the potential of our technology, and we are truly hopeful that it can make a difference in the treatment of TBI and in the precious lives of our soldiers.”

Cresilon Announces FDA 510(k) Submission For Human Use Hemostatic Gel Technology

“This FDA submission marks an important milestone for Cresilon in our commitment to significantly improve the standard of care in wound treatment,” said Joe Landolina, CEO of Cresilon.

Cresilon Closes $38.5 Million Series A-3 Financing

This financing is expected to allow the company to aggressively accelerate its global growth plan and expand the rollout of VETIGEL®.
Media Inquiries
For media inquiries and requests, please contact:
Greg Salsburg

Subscribe to our Newsletter

Stay in touch with us to get Cresilon’s news, investment opportunities, and product releases. 


122 18th St, Brooklyn, NY 11215 USA

Call Us

(347) 435-2226

Email Us